top of page

Antibody Discovery Enabled by Deep Learning

deepCDR uses unique Deep Learning methods combined with its proprietary mammalian display process to select from a massively wide range of antibodies and rapidly identify candidates with the highest possible affinity and developability profiles.

Now part of Alloy Therapeutics. Learn More.

Alloy_Therapeutics_logo_white_RGB (2).png
bottom of page